
iRadimed Corporation: updates and filings
Price
$82.31
November 18, 2026Market cap $1.1B
What Ploutos Investor adds for iRadimed
Part of Ploutos Investor, €9.99 a month
- The full history: 13 fiscal years, from 2013
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Oct 30, 2026next Feb 1, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
October 2026
July 2026
May 2026
February 2026
December 2025
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Oct 30, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Oct 30, 2026Results of operationsForm8-K
- Oct 27, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 18, 2026Results of operations (amendment)Form8-K/A
- Jul 31, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Jul 31, 2026Other material eventsForm8-K
- Jul 28, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jun 24, 2026Shareholder voteForm8-K
- May 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 1, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 1, 2026Results of operationsForm8-K
- Apr 30, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 30, 2026Annual meeting proxy statementFormDEF 14A
- Mar 6, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Feb 10, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Feb 10, 2026Results of operationsForm8-K
- Dec 8, 2025Other material eventsForm8-K
- Nov 3, 2025Quarterly reportfor the period to Sep 30, 2025Form10-Q
- Nov 3, 2025Results of operationsForm8-K
- Sep 17, 2025Letter from the SECFormUPLOAD
- Sep 3, 2025Annual report (amendment)for the period to Dec 31, 2024Form10-K/A
- Sep 3, 2025Correspondence with the SECFormCORRESP
- Sep 2, 2025Officer or director change, Regulation FD disclosureForm8-K
- Aug 20, 2025Letter from the SECFormUPLOAD
- Aug 1, 2025Quarterly reportfor the period to Jun 30, 2025Form10-Q
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Oct 30, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Oct 30, 2026 | 8-K | Results of operations | Document |
| Oct 27, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 18, 2026 | 8-K/A | Results of operations (amendment) | Document |
| Jul 31, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Jul 31, 2026 | 8-K | Other material events | Document |
| Jul 28, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jun 24, 2026 | 8-K | Shareholder vote | Document |
| May 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 1, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 1, 2026 | 8-K | Results of operations | Document |
| Apr 30, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 30, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Mar 6, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Feb 10, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Feb 10, 2026 | 8-K | Results of operations | Document |
| Dec 8, 2025 | 8-K | Other material events | Document |
| Nov 3, 2025 | 10-Q | Quarterly reportfor the period to Sep 30, 2025 | Document |
| Nov 3, 2025 | 8-K | Results of operations | Document |
| Sep 17, 2025 | UPLOAD | Letter from the SEC | Document |
| Sep 3, 2025 | 10-K/A | Annual report (amendment)for the period to Dec 31, 2024 | Document |
| Sep 3, 2025 | CORRESP | Correspondence with the SEC | Document |
| Sep 2, 2025 | 8-K | Officer or director change, Regulation FD disclosure | Document |
| Aug 20, 2025 | UPLOAD | Letter from the SEC | Document |
| Aug 1, 2025 | 10-Q | Quarterly reportfor the period to Jun 30, 2025 | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Apr 25, 2005.
The full analysis
What do iRadimed's filings show?
The filings are where every one of iRadimed's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.